

News Release
FOR IMMEDIATE RELEASE
March 3, 2015

FOR MORE INFORMATION
Julie-Ann Cabana
(514) 213-8000
icabana@vinceandassociates.com



Vince & Associates Clinical Research Completes CymaBay Therapeutics' Clinical Trial of Arhalofenate in Combination with Febuxostat

Overland Park, Kansas - [Vince & Associates Clinical Research](#), a premier provider of early phase clinical research services, announced the completion of [CymaBay Therapeutics'](#) Phase II clinical trial of [arhalofenate](#) administered in combination with [febuxostat](#) ([Uloric™](#), [Takeda Pharmaceutical Company Limited](#)) by successfully enrolling thirty two study volunteers diagnosed with gout. Arhalofenate is being tested for the treatment of gout.

"It has been a pleasure to work with the team at Vince & Associates. Operationally, the study was quite challenging but all our objectives regarding time-lines and quality were met," said Pol Boudes, MD, Chief Medical Officer of CymaBay Therapeutics.

Vince & Associates has been highly successful in conducting clinical trials in special populations such as gout based on their access to a large database of volunteers, which allows for rapid study enrollment. In addition, the physicians are experienced in the identification of appropriate study subjects for many types of special population studies and have conducted multiple studies involving gout study volunteers.

Dr. Brad Vince, CEO and Medical Director stated, "Vince & Associates appreciates the opportunity of working with the professional team at CymaBay and our involvement in bringing a potentially promising new compound for the treatment of gout to market."

About Vince & Associates Clinical Research

[Vince & Associates Clinical Research](#) has provided clinical research services to the biopharmaceutical industry for 15 years. The research professionals at Vince & Associates are proud to be recognized in the industry as a "Center of Research Excellence."

Vince & Associates currently operates a state-of-the-art, multimillion-dollar, 100-bed clinical pharmacology unit that combines the ultimate in subject safety and luxury. This early development unit has the upscale atmosphere necessary for the recruitment and retention of study volunteers in both short- and long-term clinical trials. From the safety and security of the controlled access unit to the added features of a movie theater and game rooms, no detail has been overlooked.

About Altasciences

[Altasciences](#) is the parent company of wholly owned subsidiaries Vince & Associates Clinical Research (Kansas, USA) and Algorithm Pharma (Quebec, Canada). Both organizations provide comprehensive early stage clinical services in Phase I/IIa, including the necessary support services in this critical stage of drug development.

More Information

Additional background materials pertaining to Vince & Associates Clinical Research are located on the corporate website at www.vinceandassociates.com.

#